Aurobindo Pharma Q4 FY26 Results: PAT Rs 923 Cr

Aurobindo Pharma Q4 FY26 results were declared on May 21, 2026. The company reported PAT of Rs 923 crore for the quarter ended March 31, 2026, down 1.0% YoY compared to Rs 935 crore in Q4 FY25. Revenue from operations stood at Rs 8,853 crore, up 5.0% YoY. Results are on a Consolidated basis. Aurobindo Pharma is a Pharmaceuticals company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Aurobindo Pharma Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue	8,853	8,382	+5.0%
Gross Profit	Rs 1,274 crore	1,347	-5.0%
Net Profit	923	935	-1.0%
Basis	Consolidated

Note: Aurobindo Pharma Q4 FY26 results declared May 21, 2026. Verify from BSE/NSE audited filings before investment decisions.

Aurobindo Pharma Q4 FY26 Performance Analysis

The Aurobindo Pharma Q4 FY26 results reflect the company’s operational performance in the January to March 2026 quarter. The company delivered steady performance in line with sector trends. Aurobindo Pharma operates in the Pharmaceuticals sector, which benefited from India’s GDP growth above 6.5% in FY26.

Revenue of Rs 8,853 crore reflects steady business conditions in the Pharmaceuticals sector.

Screen the best stocks on the Univest Screener.

Key Factors Driving Aurobindo Pharma Q4 FY26 Results

Revenue and Business Performance

it revenue of Rs 8,853 crore was up 5.0% YoY. Revenue momentum reflects steady demand in the Pharmaceuticals business.

Profitability and Margins

the business PAT of Rs 923 crore down 1.0% YoY. Sustaining profitability while scaling revenues remains the key management priority.

India Macro Backdrop

The January to March 2026 quarter benefited from India’s GDP growth above 6.5%, government capital expenditure of Rs 11.21 lakh crore for FY27, and resilient domestic consumption. RBI’s accommodative stance supported credit and demand conditions. The Pharmaceuticals sector saw strong tailwinds during this period.

FY27 Outlook

Following the firm results, management commentary on FY27 revenue guidance, margin expansion roadmap, and capital allocation will be key investor watchpoints. The Pharmaceuticals sector continues to benefit from India’s long-term structural growth.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the company